Certara (CERT) Stock Forecast & Price Target

Certara is supported by a differentiated biosimulation and regulatory science franchise that helps pharmaceutical clients reduce trial burden, accelerate approvals, and improve access to medicines, which creates durable demand tied to drug development productivity. Its software engine appears especially strong, with 1Q26 software bookings up 19.4% year over year, total bookings of $115.3M, and a 106% net revenue retention rate, while a stable-to-improving end market and rising AI budgets should aid growth. Although services bookings fell 14.0%, the R&MW divestiture, improved operational focus, and a cleaner MID3/ACE structure should reduce volatility, strengthen margins, and support more consistent financial improvement.

Certara is facing weaker fundamentals because FY26 and FY27 estimates were cut after 1Q26 results, with revenue now expected at $395M in FY26 and $399M in FY27, alongside lower adj. EBITDA of $119M and $128M as divestiture effects, softer services, and ongoing AI/MIDD investment pressure growth. The R&MW divestiture appears to have delivered less financial upside than expected, while the revised FY26 outlook is weighted to 2H across software, services, and margins, signaling limited near-term execution visibility. Despite modestly favorable gross margins, 1Q26 adj. EBITDA of $31.7M fell 7.6% y/y and margin compressed to 29.7%, reinforcing concerns that Certara is still not translating its platform strategy into consistent operating leverage.